Chinese Medicine (Dec 2022)

Chaihu-Guizhi-Ganjiang Decoction is more efficacious in treating irritable bowel syndrome than Dicetel according to metabolomics analysis

  • Mingming Li,
  • Jiawei Zhu,
  • Xuan Liu,
  • Zhiying Dong,
  • Jigui Tang,
  • Cian Zhang,
  • Jianpeng Jiao,
  • Jiani Chen,
  • Fenghao Yin,
  • Shi Qiu,
  • Feng Zhang,
  • Shouhong Gao,
  • Zhipeng Wang,
  • Xia Tao,
  • Xiaoqiang Yue,
  • Lianna Sun,
  • Wansheng Chen

DOI
https://doi.org/10.1186/s13020-022-00695-4
Journal volume & issue
Vol. 17, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Chaihu-Guizhi-Ganjiang Decoction (CGGD) is a traditional Chinese medicine (TCM) prescription used to treat viral influenza. There is evidence that CGGD can be used to treat irritable bowel syndrome (IBS) but the potential mechanism of action and metabolites produced upon CGGD treatment remains elusive. Methods Patients with IBS were treated with pinaverium bromide (Dicetel™) and then CGGD after a washout period of 1 week. Both treatments lasted for 30 days. The efficacy and changes of metabolites in plasma after the two treatments were compared. Plasma samples were acquired before and after each treatment, and untargeted metabolics analysis was performed. Results Efficacy was measured according to the Rome IV criteria and TCM theory. Our results indicated that CGGD showed significantly better efficacy than Dicetel in the treatment of IBS utilizing each criterion. CGGD exerted greater effects on plasma metabolism than Dicetel. Dicetel treatment led to increased tryptophan metabolism (increased levels of 5-Hydroxyindoleacetaldehyde) and increased protein metabolism (increased levels of L-arginine). CGGD treatment significantly (p < 0.05) increased carnitine metabolism, with elevated levels of L-carnitine and acylcarnitine in plasma. Such changes in these metabolites could exert effects against IBS by improving gastrointestinal motility and suppressing pain, depression, and inflammation. Conclusions CGGD appeared to be more efficacious than Dicetel for treating patients with IBS. The findings provide a sound support for the underlying biomolecular mechanism of CGGD in the prevention and treatment of IBS.

Keywords